Q2 2022 Isofol Medical AB (publ) Earnings Call Transcript
()-
Thank you so much. And let's change slide to slide number 4.
So we are presenting the second-quarter results. Keep in mind then that we had a press release couple of weeks ago detailing our study results, the topline results showing that we did not achieve our endpoints. So if we take a look at the company at a glance, it was founded in Gothenburg 40 years ago. We have a strong financial position. We are listed on Nasdaq Stockholm.
We have been developing [Avastin drug] arfolitixorin for the treatment of colorectal cancer. We have a small experienced team in Gothenburg, and we've been very pragmatically working with work orders being data driven. And our vision was to contribute to extending lives and improving quality of life for the poor people suffering from metastatic colorectal cancer, a disease with a remaining still high unmet medical need.
If we go to the next slide on page 5, this is a little bit of depiction of the Phase III study, the AGENT study. We have the control arm being modified
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |